MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company

08/05/2015 - 2 minutes

MorphoSys has acquired the Dutch biopharmaceutical company Lanthio Pharma. Morphosys already held 19.98% of Lanthio Pharma and will now pay €20M to purchase all outstanding shares. Thanks to the transaction MorphoSys can add Lanthio Pharma’s lead compound, LP2, to its growing proprietary portfolio.

The compound, a novel lanthipeptide in development for diabetic nephropathy and fibrotic diseases, will be re-named MOR107 and is planned to enter clinical trials in 2016. LP2 has demonstrated potent angiotensin II type 2 (AT2) receptor-dependent activity in vivo. The compound has the potential to be a first-in-class treatment for various fibrotic diseases and thus represents a commercially attractive opportunity for MorphoSys.

The company will pay €20M to acquire the outstanding share capital of Lanthio Pharma from the other investors. Amongst them are INKEF Capital, BioGeneration Ventures and Hanzepoort. The German company has followed Lanthio’s developments since the beginning of their relationship, when MorphoSys made its initial equity investment in November 2012 as part of Lanthio Pharma’s Series A financing round.

Jens Holstein,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member